NCT01267994View on ClinicalTrials.gov

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Sensorineural Hearing LossAutoimmune Inner Ear Disease
Interventions
DRUG

Anakinra

100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.

Trial Locations (1)

11040

North Shore-LIJ Hearing and Speech Center, New Hyde Park

All Listed Sponsors
collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

lead

Andrea Vambutas

OTHER

NCT01267994 - A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease | Biotech Hunter | Biotech Hunter